Skip to main content
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: Exp Hematol. 2012 Feb 2;40(6):445–456. doi: 10.1016/j.exphem.2012.01.015

Figure 2.

Figure 2

A. K562 were engineered to express PSGL-1 (K562/PSGL-1). B. K562 and K562/PSGL-1 have low endogenous levels of fucosylation and become heavily fucosylated following treatment with FT-VI. C. Only FT-VI-treated (fucosylated) K562/PSGL-1 cells showed improved homing to femoral marrow.